分子预测直肠癌新辅助放化疗后pCR的研究进展

Research Progress on Molecular Prediction of pCR after Neoadjuvant Chemoradiation for Rectal Cancer

局部晚期直肠癌(LARC)目前的基本治疗策略是新辅助放化疗(nCRT)和随后的全直肠系膜切除术(TME)。nCRT后的肿瘤消退在个体间差异显著,病理完全缓解(pCR)是LARC的预后因素。明确放化疗反应的预测因素有助于临床医生鉴别可能从多模式治疗中获益的患者,并在早期对其预后进行评估。本文结合近年的相关研究,探讨LARC在新辅助治疗后可能达到pCR的分子预测因子。

The current primary treatment strategy for locally advanced rectal cancer(LARC) includes neoadjuvant chemoradiation(nCRT) with subsequent total mesorectal excision. Tumor regression after nCRT varies substantially among individuals and pathological complete response(pCR) is a known prognostic factor for LARC. The identification of predictive factors for response to chemoradiotherapy would help clinicians to identify patients who would probably benefit from multimodal treatment and to perform an early assessment of individual prognosis. This article reviews recent studies to explore molecular predictors of pCR after neoadjuvant therapy for LARC patients.